In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.
about
The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulationModular Approach to Select Bacteriophages Targeting Pseudomonas aeruginosa for Their Application to Children Suffering With Cystic FibrosisA proposed integrated approach for the preclinical evaluation of phage therapy in Pseudomonas infections.Characterization of the first double-stranded RNA bacteriophage infecting Pseudomonas aeruginosa.Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing.The temperate Burkholderia phage AP3 of the Peduovirinae shows efficient antimicrobial activity against B. cenocepacia of the IIIA lineage.'Get in Early'; Biofilm and Wax Moth (Galleria mellonella) Models Reveal New Insights into the Therapeutic Potential of Clostridium difficile Bacteriophages.Pseudomonas predators: understanding and exploiting phage-host interactions.Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection.The O-specific polysaccharide lyase from the phage LKA1 tailspike reduces Pseudomonas virulence.Differential Effect of Newly Isolated Phages Belonging to PB1-Like, phiKZ-Like and LUZ24-Like Viruses against Multi-Drug Resistant Pseudomonas aeruginosa under Varying Growth Conditions.Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa biofilms and treats acute infections in two animal models.Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review.Bacteriophage Infectivity Against Pseudomonas aeruginosa in Saline Conditions.Bacteriophage Therapy: Clinical Trials and Regulatory HurdlesThe therapeutic potential of bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model
P2860
Q26748672-0FA280AC-D590-41FF-B08B-9E352E485931Q28076246-897D5131-214C-433C-82C8-9EE1A1B424CBQ36052205-D74CE4AB-30B6-4467-904C-2BD8F956BAF3Q37488110-8AAE6376-9986-4342-BF84-8594BE075C1DQ38686917-537929A6-167F-42AF-86EA-34298146DD36Q39259998-521166C1-D1CF-4524-A24E-761EE0835575Q39388122-416A80BA-1078-45CF-AB54-D0EDD07ACF74Q39397651-676E2E03-4116-4DA8-920A-756968CED374Q40058358-5082B207-228D-46C7-AA3A-A83CF5896E35Q47130097-FDFAA62A-AE7A-4FFE-BBA3-FD2B9FA54001Q47150323-CF24B964-6EE4-4C5D-89E3-8838D2D84C2AQ52648083-E66C727F-6F05-474F-A00E-01E523A30439Q54205022-811597D7-574C-4126-AFDD-06D0CD57A480Q54209321-D4E6FF8D-13EC-4321-A95B-033B035F741CQ58571995-8060DA2E-94CC-4451-BE50-6296F3773161Q58782159-6A0B62E8-3C5F-4E69-85B4-905E013C586A
P2860
In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
In vitro and in vivo antibacte ...... from cystic fibrosis patients.
@ast
In vitro and in vivo antibacte ...... from cystic fibrosis patients.
@en
type
label
In vitro and in vivo antibacte ...... from cystic fibrosis patients.
@ast
In vitro and in vivo antibacte ...... from cystic fibrosis patients.
@en
prefLabel
In vitro and in vivo antibacte ...... from cystic fibrosis patients.
@ast
In vitro and in vivo antibacte ...... from cystic fibrosis patients.
@en
P2093
P2860
P50
P1476
In vitro and in vivo antibacte ...... from cystic fibrosis patients.
@en
P2093
Daria Augustyniak
Katarzyna Danis-Wlodarczyk
Paulina Zarnowiec
Pavel Drevinek
P2860
P2888
P304
P356
10.1007/S00253-015-6492-6
P407
P577
2015-03-12T00:00:00Z